Antibiogram-guided ceftriaxone–tazobactam therapy for acute mastitis in Murrah buffaloes

Abstract

Acute mastitis remains a major production-limiting disease in dairy buffaloes, particularly during early lactation. The present clinical study evaluated the therapeutic efficacy of a combination of Ceftriaxone and Tazobactam along with multivitamin supplementation in recently calved Murrah buffaloes. Nine clinical cases were subjected to bacteriological examination and antibiogram assay prior to treatment. Ceftriaxone exhibited the highest zone of inhibition (32 mm) against isolated pathogens and was selected for therapy. Animals were treated intramuscularly for five consecutive days. Significant reduction in Somatic Cell Count (SCC) and Total Bacterial Count (TBC) was observed by day 7 and day 16 post-treatment. Complete clinical recovery and improvement in milk quality were recorded, with no recurrence up to 21 days post-therapy. The findings support the use of Ceftriaxone–Tazobactam combination therapy guided by antibiogram testing for effective management of acute mastitis in buffaloes.